(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Lenz Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast LENZ's revenue for 2025 to be $198,832,007, with the lowest LENZ revenue forecast at $151,485,807, and the highest LENZ revenue forecast at $275,428,740. On average, 5 Wall Street analysts forecast LENZ's revenue for 2026 to be $1,298,040,566, with the lowest LENZ revenue forecast at $1,148,317,503, and the highest LENZ revenue forecast at $1,408,818,005.
In 2027, LENZ is forecast to generate $3,316,575,173 in revenue, with the lowest revenue forecast at $2,892,001,770 and the highest revenue forecast at $3,787,145,175.